Articles by tag: dolutegravir

Pediatric Dovato: ViiV application and geopolitics of the HIV market

ViiV has submitted applications to the FDA and EMA for dispersible Dovato tablets for children. We analyze the strategy, patents, and implications. Find out who will win.

EMA accepted the application for Dovato for children with HIV

EMA validated the application for the use of Dovato in children from 3 months with HIV. Learn how this will change pediatric therapy and strengthen ViiV's position. Read the detailed analysis.

Pediatric Dovato: EMA Approves Application for HIV Therapy

EMA validated the application for pediatric Dovato (dolutegravir/lamivudine) for children from 2 years old. Learn how two-drug therapy is changing HIV treatment standards.